Literature DB >> 1982460

Delta and kappa opiate receptors in primary astroglial cultures from rat cerebral cortex.

P S Eriksson1, E Hansson, L Rönnbäck.   

Abstract

The effects of mu, delta, and kappa receptor-agonists on forskolin stimulated cyclic adenosine-3',5'-monophosphate (cAMP) formation were examined in astroglial enriched primary cultures from the cerebral cortex of newborn rats. Intracellular cAMP accumulation was quantified by radioimmunoassay. Morphine was used as a mu-receptor agonist, D-Ala-D-Leu-Enkephalin (DADLE) as a delta-receptor agonist and dynorphin 1-13 (Dyn) as a kappa-receptor agonist. Basal cAMP levels were unaffected by either the opiate agonists or the antagonists used. In the presence of the cAMP stimulator forskolin, morphine had no significant effect on the cytoplasmic cAMP levels. DADLE caused a dose related inhibition of the forskolin stimulated cAMP accumulation. The effects of this delta receptor stimulation was blocked with the selective antagonist ICI 174.864. In the presence of Dyn, the forskolin stimulated cAMP accumulation was inhibited in a dose related manner. This kappa receptor stimulation was blocked with the selective antagonist MR 2266. Co-administration of DADLE and Dyn resulted in a non additive inhibition of the forskolin stimulated accumulation of cAMP. These findings indicate that astroglial enriched cultures from the cerebral cortex of rats express delta and kappa-receptors co-localized on the same population of cells, and that these receptors are inhibitory coupled to adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982460     DOI: 10.1007/bf01101714

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  32 in total

1.  Ontogenesis of delta-opioid receptors in rat brain using [3H][D-Pen2,D-Pen5]enkephalin as a binding ligand.

Authors:  J McDowell; I Kitchen
Journal:  Eur J Pharmacol       Date:  1986-09-09       Impact factor: 4.432

2.  Radioimmunoassay for cyclic nucleotides. II. Adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in mammalian tissues and body fluids.

Authors:  A L Steiner; A S Pagliara; L R Chase; D M Kipnis
Journal:  J Biol Chem       Date:  1972-02-25       Impact factor: 5.157

3.  A phosphoinositide-linked peptide response in astrocytes: evidence for regional heterogeneity.

Authors:  A J Cholewinski; M R Hanley; G P Wilkin
Journal:  Neurochem Res       Date:  1988-04       Impact factor: 3.996

Review 4.  Primary astroglial cultures. A biochemical and functional evaluation.

Authors:  E Hansson
Journal:  Neurochem Res       Date:  1986-06       Impact factor: 3.996

5.  Evidence for opiate receptors on pituicytes.

Authors:  S L Lightman; M Ninkovic; S P Hunt; L L Iversen
Journal:  Nature       Date:  1983 Sep 15-21       Impact factor: 49.962

6.  Inhibition of dopamine-sensitive adenylate cyclase by opioids: possible involvement of physically associated mu- and delta-opioid receptors.

Authors:  A N Schoffelmeer; F Hogenboom; A H Mulder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-03       Impact factor: 3.000

7.  Kappa opioid receptor-mediated analgesia in the developing rat.

Authors:  G A Barr; W Paredes; K L Erickson; R S Zukin
Journal:  Brain Res       Date:  1986-10       Impact factor: 3.252

8.  Astrocyte opioid receptors: activation modifies the noradrenaline-evoked increase in 2-[14C]deoxyglucose incorporation into glycogen.

Authors:  B Pearce; M Cambray-Deakin; S Murphy
Journal:  Neurosci Lett       Date:  1985-04-09       Impact factor: 3.046

9.  Demonstration and characterization of opiate inhibition of the striatal adenylate cyclase.

Authors:  P Y Law; J Wu; J E Koehler; H H Loh
Journal:  J Neurochem       Date:  1981-05       Impact factor: 5.372

10.  Interaction between catecholamines and vasoactive intestinal peptide in cultured astrocytes.

Authors:  E Hansson; L Rönnbäck
Journal:  Neuropharmacology       Date:  1988-03       Impact factor: 5.250

View more
  23 in total

Review 1.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

2.  Glial growth is regulated by agonists selective for multiple opioid receptor types in vitro.

Authors:  A Stiene-Martin; K F Hauser
Journal:  J Neurosci Res       Date:  1991-08       Impact factor: 4.164

3.  Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

4.  Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa-opioid receptor expression among cultured mouse astrocytes.

Authors:  A Stiene-Martin; R Zhou; K F Hauser
Journal:  Glia       Date:  1998-03       Impact factor: 7.452

5.  Evidence for kappa- and mu-opioid receptor expression in C6 glioma cells.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  1998-05       Impact factor: 5.372

Review 6.  Physiology of Astroglia.

Authors:  Alexei Verkhratsky; Maiken Nedergaard
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

7.  kappa-Opioid agonist modulation of [3H]thymidine incorporation into DNA: evidence for the involvement of pertussis toxin-sensitive G protein-coupled phosphoinositide turnover.

Authors:  J Barg; M M Belcheva; J Rowiński; C J Coscia
Journal:  J Neurochem       Date:  1993-04       Impact factor: 5.372

8.  Chronic treatment of newborn rats with naltrexone alters astrocyte production of nerve growth factor.

Authors:  K Mitsuo; J P Schwartz
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

9.  Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro.

Authors:  S K Buch; V K Khurdayan; S E Lutz; P E Knapp; N El-Hage; K F Hauser
Journal:  Neuroscience       Date:  2007-05-02       Impact factor: 3.590

10.  Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.

Authors:  Theresa-Alexandra M Mattioli; Brian Milne; Catherine M Cahill
Journal:  Mol Pain       Date:  2010-04-16       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.